Figure 3.

A summary of the patient’s clinical course.
The decline in forced vital capacity accelerated with the appearance of joint involvement.
anti-CCP antibody, anti-cyclic citrullinated peptide antibody; BAL, bronchoalveolar lavage; PSL, prednisolone; SASP, salazosulfapyridine; TBLB, transbronchial lung biopsy.